User Blocked from Social Media Platform

South Africa is grappling with a surge in illegal weight‑loss drugs as people turn to unregistered versions of GLP‑1 medicines in hopes of shedding pounds that diet and exercise alone have failed to reduce.

High cost drives consumers to the black market

In South Africa, the price tag of R3 000 to R6 000 per month makes GLP‑1 medicines inaccessible for most patients, according to health officials.

When a medication is priced beyond what the average household can afford, a parallel market often emerges. Unregistered formulations—sometimes marketed as “cat food” or “calcium”—appear on online platforms and are shared through gym WhatsApp groups. Buyers typically have no insight into the ingredients or safety profile of these products.

Local pharmacy iDexis was recently ordered by the Gauteng Division of the High Court in Tshwane to cease compounding GLP‑1 medicines. The regulator, SAHPRA, also instructed the company to recall any weight‑loss products it had already produced. The court’s decision reflects growing concerns over the quality and legality of these alternatives.

Medical community faces enforcement challenges

Even some physicians have prescribed the illicit versions, SAHPRA said, highlighting the difficulty of monitoring a market that is still in its infancy. “It is hard to keep track of illegal sales in this burgeoning industry,” the agency noted in a recent statement.

Obesity itself is linked to a higher likelihood of type 2 diabetes and heart disease, making the stakes of unsafe medication use especially high. Researchers stress that without proper medical oversight, the potential harms may outweigh any short‑term benefits.

While the illegal trade flourishes, public health advocates argue that a broader solution is needed. Francois Venter, a researcher at the health organization Ezintsha at Wits University, says that introducing affordable generic GLP‑1 options could undercut the black market. He also calls for a shift in public perception, noting that “diet and exercise alone cannot help people lose weight” for many individuals.

From a policy perspective, the situation highlights a classic dilemma: high‑priced, effective treatments can unintentionally fuel illicit markets. If governments can negotiate lower prices or support local production of safe generics, the incentive to seek out unregulated alternatives might diminish. This approach mirrors strategies used in other therapeutic areas where price barriers have spurred counterfeit drug proliferation.

Regulatory response and future outlook

SAHPRA has intensified inspections and is working with customs officials to intercept shipments labeled under innocuous categories. The agency also plans to launch an awareness campaign aimed at educating consumers about the dangers of unverified weight‑loss products.

Meanwhile, the court’s injunction against iDexis serves as a warning to other compounding pharmacies that may be tempted to fill the demand gap. Continued enforcement, combined with clearer guidelines for legitimate prescribing, could help stabilize the market.

In the short term, individuals looking to lose weight are advised to consult qualified healthcare providers and to verify that any medication they receive is approved by the national regulator. The risk of unknown contaminants and inconsistent dosing remains a serious concern for those who opt for the cheaper, untested options.